Plaque brachytherapy for choroidal melanoma: strategies and techniques to reduce risk and maximize outcomes

References

• Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50:147–155.
   PubMed Web of Science ®Google Scholar
• Lommatzsch PK. Results after beta-irradiation 106Ru/106Rh of choroidal melanomas: 20 years’ experience. Br J Ophthalmol. 1986;70:844–851.
   PubMed Web of Science ®Google Scholar
• Packer S, Stoller S, Lessor ML, et al. Long-term results of 125I irradiation of uveal melanoma. Ophthalmology. 1992;99:767–774.
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ, Duval G; For the Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116(4):790–796.
   PubMed Web of Science ®Google Scholar
• Ophthalmic Radiotherapy: Plaques and Implants. Finger PT, Rivard MJ, Chaugule SS, et al. In: Chaugule SS, Honavar SG, Finger PT, editors. Surgical Ophthalmic Oncology: A Collaborative Open Access Reference. Springer Nature Switzerland, Open Access. 2019, Part IV, Chapter 14, pp. 147–160.
   Google Scholar
• The American Brachytherapy Society - Ophthalmic Oncology Task Force. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.
   PubMed Web of Science ®Google Scholar
• Chiu-Tsao ST, Astrahan MA, Finger PT, et al. Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: report of task group 129 by the AAPM and ABS. Med Phys. 2012;39(10):6161–6184.
   PubMed Web of Science ®Google Scholar
• Little JB. Principal cellular and tissue effects of radiation. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei cancer medicine. 6th. ed. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK12344/
   Google Scholar
• Chaugule SS, Finger PT. Regression patterns of iris melanoma after palladium-103 (103Pd) plaque brachytherapy. Ophthalmology. 2017;124(7):1023–1030.
   PubMed Web of Science ®Google Scholar
• Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 2001;132(3):328–335.
   PubMed Web of Science ®Google Scholar
• Saornil MA, Egan KM, Gargoudas ES, et al. Histopathology of proton beam-irradiated vs. enucleated uveal melanomas. Arch Ophthalmol. 1992;110:11121118.
   Google Scholar
• Shields CL, Shields JA, Karlsson U, et al. Enucleation after plaque radiotherapy for posterior uveal melanoma. Ophthalmology. 1990;97(12):1665–1670.
   PubMed Web of Science ®Google Scholar
• Eckert and Ziegler Corporation. 2020;1–8. Available from: https://www.bebig.com/fileadmin/bebig_neu/user_uploads/Products/Ophthalmic_Brachytherapy/Ophthalmic_Brochure__Rev._06__English.pdf 2020, pp.1–8.
   Google Scholar
• Maheshwari A, Finger PT. A 12-year study of slotted palladium-103 plaque radiation therapy for choroidal melanoma: near, touching or surrounding the optic nerve. Am J Ophthalmol. 2018;188:60–69.
   PubMed Web of Science ®Google Scholar
• Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42(3):215–232.
   PubMed Web of Science ®Google Scholar
• Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068–1070.
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ, Yu GP. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010;149(4):608–615.
   PubMed Web of Science ®Google Scholar
• Yousef YA, Finger PT. Lack of radiation maculopathy after palladium-103 plaque radiation therapy for iris melanoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1107–1112.
   PubMed Web of Science ®Google Scholar
• Finger PT, Zhou D, Kalach N, et al. 103Pd versus 125I ophthalmic plaque brachytherapy: preoperative comparative dosimetry in 319 uveal melanomas. J Radiat Oncol. 2014;3(4):409–416.
   PubMedGoogle Scholar
• Barker CA, Francis JH, Cohen GN, et al. 106Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy. 2014;13(6):584–590.
   PubMed Web of Science ®Google Scholar
• Fili M, Trocme E, Bergman L, et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness ≥5.5 mm. Br J Ophthalmol. 2020;104(1). In press. DOI:10.1136/bjophthalmol-2018-313419
   PubMed Web of Science ®Google Scholar
• Eghari EO, Riazuddin SA, Gottsch JD. Overview of the cornea: structure, development and function. In: Hejtmancik JF, Nickerson JM, editors. Progress in molecular biology and translational science. Vol. 134. New York: Elsevier; 2015. Chapter 2, p. 7–23.
   Google Scholar
• Finger PT. Finger’s amniotic membrane buffer technique protecting the cornea during radiation plaque therapy. Arch Ophthalmol. 2008;126(4):531–534.
   PubMedGoogle Scholar
• Nagendran ST, Finger PT, Campolattaro BN. Extraocular muscle repositioning and diplopia: associated with ophthalmic plaque radiation therapy for choroidal melanoma. Ophthalmology. 2014;121(11):2268–2274.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Murray TG, Byrne SF, et al. Intraoperative echographic localization of iodine-125 episcleral radioactive plaques for posterior uveal melanoma. Retina. 1996;16(2):129–134.
   PubMed Web of Science ®Google Scholar
• The Ophthalmic Oncology Task Force. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91.
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin ®) for radiation retinopathy. Arch Ophthalmol. 2007;125(6):751–756.
   PubMedGoogle Scholar
• Finger PT. Anti-VEGF bevacizumab (Avastin ®) for radiation optic neuropathy. Am J Ophthalmol. 2007;143(2):335–338.
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ, Semenova E. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur J Ophthalmol. 2016;26(1):60–66.
   PubMed Web of Science ®Google Scholar
• Powell BE, Finger PT. Immediate post-plaque anti-VEGF therapy prevents or delays radiation maculopathy. Ophthalmol Retina. 2020;4(5):547–550.
   PubMedGoogle Scholar
• Finger PT, Rivard MJ, Chaugule SS, et al. Ophthalmic radiotherapy: plaques and implants. In: Chaugule SS, Honavar S, Finger PT, editors. Surgical ophthalmic oncology: a collaborative open access reference. Switzerland (AG): Springer Nature; 2019. Part VI, Chapter 14, p. 147–160.
   Google Scholar
• Finger PT, Chin KJ, Yu GP, et al.; For The Palladium-103 for Choroidal Melanoma Study Group. Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys. 2011;80(3):800–806.
   PubMed Web of Science ®Google Scholar